Date: 2015-06-10
Type of information: Publication of results in a medical journal
phase:
Announcement: publication of results in Molecular Therapy
Company: Cellectis (France)
Product: allogeneic CAR T-cells
Action
mechanism: cell therapy/immunotherapy product/gene therapy.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 10, 2015, Cellectis announced the publication of a study in Molecular Therapy, describing the development of the next generation of engineered CAR T-cells compatible with allogeneic adoptive transfer immunotherapy (A Multidrug Resistant Engineered CAR T-Cell for Allogeneic Combination Immunotherapy). The adoptive transfer of allogeneic CAR T-cells represents a promising strategy to fight multiple cancers worldwide. Cellectis has streamlined an engineering process to generate CAR T-cells that could be compatible with allogeneic adoptive transfer in combination with nucleoside analogues lymphodepleting drugs. When allogeneic CAR T-cell infusion is considered, host versus graft and graft versus host reactions must be avoided to prevent rejection of adoptively transferred cells, host tissue damages and to elicit significant antitumoral outcome. In this report, Julien Valton Ph.D. and his collaborators addressed these requirements by
developing a multidrug resistant TCRαβ-deficient CAR T-cell. This engineered T-cell displayed efficient antitumor activity and significant resistance to purine and pyrimidine nucleoside analogues, which are currently used clinically in preconditioning lymphodepleting regimens. Their properties could prevent their alloreactivity and enable control over engraftment in patients. In addition, they are compatible in combination therapy, an approach likely to improve clinical outcomes. By providing a basic framework to develop a universal Tcell compatible with allogeneic adoptive transfer, Cellectis is laying the foundation for the
large-scale utilization of CAR T-cell immunotherapies.
